



PCT #5
DT07 Rec'd PCT TO 05 APR 2004

Dkt. 0575/58040-A-PCT-US/JPW/BJA

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

Applicants : Jonathan M. Barasch et al.
U.S. Serial No.: 09/980,853 Int'l App'l No. PCT/US00/12536
Entered U.S. : November 2, 2001 Int'l Filing Date: May 4, 2000
National Stage
For : A METHOD OF INDUCING FORMATION OF KIDNEY EPITHELIA FROM MESENCHYMAL PRECURSORS

1185 Avenue of the Americas
New York, New York 10036
April 2, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

PETITION TO WITHDRAW HOLDING OF ABANDONMENT IN RESPONSE TO
FEBRUARY 24, 2004
NOTIFICATION OF DEFECTIVE RESPONSE ABANDONMENT

This Petition is submitted in response to a Notification Of Defective Response Abandonment issued February 24, 2004 in connection with the above-identified application. A copy of the Notification is attached hereto as **Exhibit A**. A response to the February 24, 2002 Notification is due April 24, 2004. Accordingly, this Petition is being timely filed.

Applicants: Jonathan M. Barasch et al.
U.S. Serial No.: 09/980,853, national stage of PCT/US00/12536
National Entry Date: November 2, 2001
Page 2

Background

The February 24, 2004 Notification alleges that the applicants failed to properly respond to the January 22, 2002 Notification Of Missing Requirements issued in connection with the above-identified application, a copy of which is annexed hereto as **Exhibit B**. The January 22, 2002 Notification of Missing Requirements indicated that applicants were required to submit a computer readable form Sequence Listing and a Statement in Accordance with 37 C.F.R. §1.821(f) in connection with the above-identified application.

Applicants timely submitted a Communication in Response to January 22, 2002 Notification of Missing Requirements on March 5, 2002. A copy of the return postcard for applicants' March 5, 2002 response, stamped by the Patent Office, and a copy of the response itself, without exhibits, are annexed hereto as **Exhibit C**. In their March 5, 2002 Communication, applicants noted that a paper copy Sequence Listing and a Statement in Accordance with 37 C.F.R. §1.821(f) had already been submitted by applicants in connection with the above-identified application as part of a Preliminary Amendment filed on November 2, 2001. In addition, applicants noted that as part of the same Preliminary Amendment, applicants had requested pursuant to 37 C.F.R. §1.821(e), that the Patent Office use the computer readable format Sequence Listing submitted in connection with PCT/US00/12536, filed with the U.S. Receiving Office on May 4, 2000. Accordingly, applicants contend that the January 22, 2002 Notification of Missing Requirements erroneously required applicants to submit a Sequence Listing.

However, in order to expedite prosecution, in their response to the January 22, 2002 Notification, applicants included a second request to use the computer readable format Sequence Listing submitted in

Applicants: Jonathan M. Barasch et al.
U.S. Serial No.: 09/980,853, national stage of PCT/US00/12536
National Entry Date: November 2, 2001
Page 3

connection with PCT/US00/12536, filed with the U.S. Receiving Office on May 4, 2000, and noted that the paper copy Sequence Listing and the Statement in Accordance with 37 C.F.R. §1.821(f) had already been submitted by applicants in connection with the above-identified application as part of a Preliminary Amendment filed on November 2, 2001.

Notwithstanding this second request by applicants, the United States Patent and Trademark Office issued the Notification Of Defective Response Abandonment on February 24, 2004 in connection with the above-identified application. Accordingly, because of the background facts detailed above, applicants contend that the February 24, 2004 Notification of Defective Response Abandonment should not have been issued as the response filed by applicants on March 5, 2002 was in fact complete.

Action Requested

In light of facts presented hereinabove, applicants request that the holding of abandonment be withdrawn and the subject application re-instated.

In addition, applicants hereby again note that the Sequence Listing in the subject application is identical to the Sequence Listing in the parent of the subject application, namely PCT International Application No. PCT/US00/12536, filed May 4, 2000 with the U.S. Receiving Office. However, in order to expedite prosecution, applicants attach herewith copies of the paper copy of the Sequence Listing (3 pages) (**Exhibit D**) and the Statement In Accordance With 37 C.F.R. §1.821(f) (**Exhibit E**) previously filed in connection with the above-identified application, and a computer readable form sequence Listing as filed in connection PCT/US00/12536 with as

Applicants: Jonathan M. Barasch et al.
U.S. Serial No.: 09/980,853, national stage of PCT/US00/12536
National Entry Date: November 2, 2001
Page 4

Exhibit F.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone the number provided below.


No fee is deemed necessary in connection with the filing of this Petition to Withdraw Holding of Abandonment. However, if any such fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



John P. White
Reg. No. 28,678

4/2/04

Date



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.

09/980,853

FIRST NAMED APPLICANT

Jonathan M Barasch

ATTY. DOCKET NO.

58040-A-PCT-US/JPW/FHB

INTERNATIONAL APPLICATION NO.


PCT/US00/12536

I.A. FILING DATE

05/04/2000

PRIORITY DATE

John P White
Cooper & Dunham
1185 Avenue of the Americas
New York, NY 10036



CONFIRMATION NO. 3274

371 FORMALITIES LETTER



OC000000011959466

Date Mailed: 02/24/2004

Petition to Revoke: 4/24/04 MPL

NOTIFICATION OF DEFECTIVE RESPONSE ABANDONMENT

The United States Patent and Trademark Office in its capacity as a Designated / Elected Office (37 CFR 1.495) has made the following determination:

Applicant has failed to properly respond to the notification of MISSING REQUIREMENTS (Form PCT/DO/EO/905), mailed 01/22/2002 within the time period set therein.

Therefore, the above identified application failed to meet the requirements of 35 U.S.C. 371 and 37 CFR 1.495, and is ABANDONED AS TO THE UNITED STATES OF AMERICA.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e) and PCT Rule 13ter.1(a)(ii).
 - APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase PatentIn Software, call (703) 306-2600
 - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Applicants: Jonathan M. Barasch et al.
U.S. Serial No.: 09/980,853
Filed: November 2, 2001
Exhibit A

A copy of this notice **MUST** be returned with the response

LAMONT M HUNTER

Telephone: (703) 305-3686

PART 2 - OFFICE COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/980,853	PCT/US00/12536	58040-A-PCT-US/JPW/FHB

FORM PCT/DO/EO/918 (371 Formalities Notice)



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
 United States Patent and Trademark Office
 Washington, D.C. 20231
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/980,853	Jonathan M Barasch	58040-A-PCT-US/JPW/FHB

INTERNATIONAL APPLICATION NO.

PCT/US00/12536

I.A. FILING DATE	PRIORITY DATE
------------------	---------------

05/04/2000

5/4/1999

John P White
 Cooper & Dunham
 1185 Avenue of the Americas
 New York, NY 10036

1/22/2002
 MP Due: 3/22/2002
 MP Ext: 4/22/2002
 MP Ext: 5/22/2002
 MP Ext: 6/22/2002
 MP Ext: 7/22/2002
 MP Deadline: 8/22/2002 SML

CONFIRMATION NO. 3274

371 FORMALITIES LETTER



OC000000007334451

Date Mailed: 01/22/2002

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- o U.S. Basic National Fees
- o Indication of Small Entity Status
- o Biochemical Sequence Listing
- o Copy of IPE Report
- o Copy of the International Application
- o Copy of the International Search Report
- o Oath or Declaration
- o Preliminary Amendments
- o Request for Immediate Examination
- o Small Entity Statement

JAN 29 2002

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- o Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date. The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) in that it:
 - is not executed in accordance with either 37 CFR 1.66 or 37 CFR 1.68.
- o The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
 - APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."

Applicants: Jonathan M. Barasch et al.
 U.S. Serial No.: 09/980,853
 Filed: November 2, 2001
 Exhibit B

- A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase PatentIn Software, call (703) 306-2600
 - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

LAMONT M HUNTER

Telephone: (703) 305-3686

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/980,853	PCT/US00/12536	58040-A-PCT-US/JPW/FHB

Applicant Jonathan Barasch et al.

Client 0575 (COLUMBIA)

File No. 58040-A-PCT-US IPW/ADM

Date March 5, 2002

Kindly acknowledge receipt of the accompanying

Communication In Response To January 22, 2002 Notification Of Missing Requirements Under 35 U.S.C. §371 And Information Disclosure Statement, for Jonathan Barasch et al., A METHOD OF INDUCING FORMATION OF KIDNEY EPITHELIA FROM MESENCHYMAL PRECURSORS, U.S. Serial No. 09/980,853, filed November 2, 2001, including a copy of the Notification (Exhibit A), signed Declaration and Power of Attorney (Exhibit B), Form PTO-1449 (Exhibit C), a check for \$65.00, and a Certificate of Mailing dated March 5, 2002.

DUE DATE: March 22, 2002

by placing your receiving date stamp hereon and returning to us

JC05 Rec'd PCT/PTO 12 MAR 2002

W.D.

Applicants: Jonathan M. Barasch et al.
U.S. Serial No.: 09/980,853
Filed: November 2, 2001
Exhibit C

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

Applicants : Jonathan M. Barasch et al.

U.S. Serial No.: 09/980,853

Int'l App'l No.
PCT/US00/12536

Entered U.S. : November 2, 2001
National Stage

Int'l Filing Date:
May 4, 2000

For : A METHOD OF INDUCING FORMATION OF KIDNEY
EPITHELIA FROM MESENCHYMAL PRECURSORS

1185 Avenue of the Americas
New York, New York 10036
March 5, 2002

Assistant Commissioner for Patents
BOX PCT
Washington, D.C. 20231
ATTN: DO/EO/US

Sir:

**COMMUNICATION IN RESPONSE TO JANUARY 22, 2002
NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. §371 AND
INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)(3)**

This Communication is submitted in response to a Notification Of Missing Requirements Under 35 U.S.C. §371 issued January 22, 2002 in connection with the above-identified application. A copy of the Notification is attached hereto as **Exhibit A**. A response to the January 22, 2002 Notification is due March 22, 2002. Accordingly, this Communication is being timely filed.

The Notification indicates that an oath executed in accordance with 37 C.F.R. §1.66 or a declaration executed in accordance 37 C.F.R. §1.68 is required. In response, applicants submit as **Exhibit B** hereto an original signed Declaration and Power of Attorney executed in accordance with 37 C.F.R. §1.68 and in compliance with

Applicants: Jonathan M. Barasch et al.
U.S. Serial No.: 09/980,853, national stage of PCT/US00/12536
National Entry Date: November 2, 2001
Page 2

37 C.F.R. §1.497(a) and (b). In compliance with 37 C.F.R. §1.497(a), the Declaration refers to the application's above-identified International Application Number, International Filing Date, U.S. Serial Number, and date of U.S. National entry.

The surcharge for submitting the Declaration for a small entity is the SIXTY-FIVE DOLLAR (\$65.00) fee set forth in 37 C.F.R. §1.492(e) and a check in this amount is enclosed.

Sequence Listing

The Notification indicates that a computer readable form (CRF) of the Sequence Listing has not be submitted as required by 37 C.F.R. §1.821(e).

In response, applicants respectfully refer the Examiner to the following paragraph which was included as part of the Preliminary Amendment that was filed when the subject application entered the U.S. National stage on November 2, 2001:

The Sequence Listing in the subject application is identical to the Sequence Listing in the parent of the subject application, namely PCT International Application No. PCT/US00/12536, filed May 4, 2000. Applicants attach herewith copies of the paper copy of the Sequence Listing (3 pages) and the Statement In Accordance With 37 C.F.R. §1.821(f) which were filed with PCT International Application No. PCT/US00/12536 on May 4, 2000. In accordance with 37 C.F.R. §1.821 (e), please use the computer readable form filed in PCT International Application No. PCT/US00/12536 on May 4, 2000 as the

Applicants: Jonathan M. Barasch et al.
U.S. Serial No.: 09/980,853, national stage of PCT/US00/12536
National Entry Date: November 2, 2001
Page 3

computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application.

Accordingly, in accordance with 37 C.F.R. §1.821(e), please use the computer readable form filed in PCT International Application No. PCT/US00/12536 on May 4, 2000 as the computer readable form for the instant application.

INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following references which are listed on the attached Form PTO-1449 (**Exhibit C**). These references were previously submitted or cited in connection with the prosecution of U.S. Serial No. 09/305,029. The subject application claims benefit of the filing date of U.S. Serial No. 09/305,029 under 35 U.S.C. §120. According to 37 C.F.R. §1.98(d), copies of patents or publications that were previously cited by, or submitted to, the Patent Office in connection with such prior applications need not accompany the Information Disclosure Statement. Accordingly, copies of the following references are not attached to this Information Disclosure Statement:

1. PCT International Publication No. WO 00/41713, published July 20, 2000;

2. Barasch, J., L. Pressler, J. Connor, and A. Malik. 1996. A ureteric bud cell line induces nephrogenesis in two steps by two distinct signals. *Am. J. Physiol.* 271: F50-F61;
3. Barasch, J., J. Qiao, G. McWilliams, D. Chen, J.A. Oliver, and D. Herzlinger. 1997. Ureteric bud cells secrete multiple factors, including bFGF, which rescue renal progenitors from apoptosis. *Am. J. Physiol.* 273: F757-F767;
4. Barasch, J., J. Yang, J. Qiao, P. Tempst, H. Erdjument-Bromage, W. Leung, J.A. Oliver. May, 1999. Tissue inhibitor of metalloproteinase-2 stimulates mesenchymal growth and regulates epithelial branching during morphogenesis of the rat metanephros. *J. Clin. Invest.* 103: 1299-1307;
5. Bard, J.B.L. and A.S.A. Ross. LIF, the ES-cell inhibition factor, reversibly blocks nephrogenesis in cultured mouse kidney rudiments. *Development* 113: 193-198, 1991;
6. Boccaccio, C., M. Ando, L. Tamagnone, A. Bardelli, P. Michieli, C. Battistini, and P.M. Comoglio. 1998. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. *Nature* 391: 285-288;
7. Bonni, A., Y. Sun, M. Nadal-Vicens, A. Bhatt, D. A. Frank, I. Rozovsky, N. Stahl, G.D. Yancopoulos, and M.E. Greenberg. 1997. Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. *Science* 278: 477-483;
8. Grobstein, C. 1955. Inductive interaction in the development of the mouse metanephros. *J. Exp. Zool.* 130: 319-339;
9. Gruenwald, P. 1943. Stimulation of nephrogenic tissue by normal and abnormal inductors. *Anat. Rec.* 86: 321-335;
10. Hartner, A. et al. Cytokine-induced expression of leukemia inhibitory factor in renal mesangial cells. *Kidney International* 45: 1562-1571, 1994;
11. Hartner, A. et al. Renal mesangial cells have the capacity to synthesize and react to leukemia inhibitory factor. *Ann. N.Y. Acad. Sci.* 762 (Interleukin-6-Type Cytokines): 424-425, 1995 (Abstract);

Applicants: Jonathan M. Barasch et al.

U.S. Serial No.: 09/980,853, national stage of PCT/US00/12536

National Entry Date: November 2, 2001

Page 5

12. Herzlinger, D., J. Qiao, D. Cohen, N. Ramakrishna, and A.M.C. Brown. 1994. Induction of Kidney epithelial morphogenesis by cells expressing *Wnt-1*. *Develop. Biol.* 166: 815-818;
13. Karavanova, I.D., L.F. Dove, J.H. Resau, and A.O. Perantoni. 1996. Conditioned media from a rat ureteric bud cell line in combination with bFGF induces complete differentiation of isolated metanephric mesenchyme. *Development* 122: 4159-4167;
14. Kispert, A., S. Vainio, A.P. McMahon. 1998. *Wnt-4* is a mesenchymal signal for epithelial transformation of metanephric mesenchyme in the developing kidney. *Development* 125: 4225-4234;
15. Mayer, M., Bhakoo, K., and M. Noble. 1994. Ciliary Neurotrophic factor and leukemia inhibitory factor promote the generation, maturation and survival of oligodendrocytes in vitro. *Development* 120: 143-153;
16. Morel, D.S. et al. Renal synthesis of leukemia inhibitory factor. *Cytokine* 12(3): 265-271, 2000 (Abstract);
17. Murphy, M., K. Reid, D.J. Hilton, and P.F. Bartlett. 1991. Generation of sensory neurons is stimulated by leukemia inhibitory factor. *Proc. Natl. Acad. Sci. USA* 88: 3498-3501;
18. Murphy, M., K. Reid, M.A. Brown, P.F. Bartlett. 1993. Involvement of leukemia inhibitory factor and nerve growth factor in the development of dorsal root ganglion neurons. *Development* 117: 1173-1182;
19. Murphy, M., K. Reid, M. Ford, J. B. Furness, and P. F. Bartlett. 1994. FGF2 regulates proliferation of neural crest cells, with subsequent neuronal differentiation regulated by LIF or related factors. *Development* 120: 3519-3528;
20. Perantoni, A.O., L.F. Dove and I. Karavanova. 1995. Basic fibroblast growth factor can mediate the early inductive events in renal development. *Proc. Natl. Acad. Sci. USA*. 92: 4696-4700;
21. Sariola, H., P. Ekblom, S. Henke-Fahle. 1989. Embryonic neurons as *in vitro* inducers of differentiation of nephrogenic mesenchyme. *Devel. Biol.* 132: 271-281;

Applicants: Jonathan M. Barasch et al.
U.S. Serial No.: 09/980,853, national stage of PCT/US00/12536
National Entry Date: November 2, 2001
Page 6

22. Stark, K., S. Vainio, G. Vassileva, A. P. McMahon. 1994. Epithelial transformation of metanephric mesenchyme in the developing kidney regulated by *Wnt-4*. *Nature* 372: 679-683;
23. Taupin, J.L. et al. HILDA-LIF urinary excretion during acute kidney rejection. *Transplantation* 53(3): 655-658, 1992 (Abstract); and
24. Wallner, E.I. et al. Growth factors in metanephric development. *Renal Failure* 20(2): 331-341, 1998 (Abstract).


Applicants are submitting this Information Disclosure Statement under 37 C.F.R. §1.97(b) (3) before the mailing of a first Office Action on the merits. Accordingly, no fee is deemed necessary in connection with the filing of this Information Disclosure Statement.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone the number provided below.


Applicants: Jonathan M. Barasch et al.
U.S. Serial No.: 09/980,853, national stage of PCT/US00/12536
National Entry Date: November 2, 2001
Page 7

No fee, other than the enclosed \$65.00 surcharge for filing the attached Declaration, is deemed necessary in connection with the filing of this Communication and Information Disclosure Statement. However, if any other fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, BOX PCT, Washington, D.C. 20231.


Alan D. Miller
Reg. No. 42,889

Date

John P. White
Registration No. 28,678
Alan D. Miller
Registration No. 42,889
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

SEQUENCE LISTING

<110> The Trustees of Columbia University in the City of

<120> Method of Inducing Formation of Kidney Epithelia From
Mesenchymal Precursors

<130> 58040-A-PCT/JPW

<140>

<141>

<150> 09/305,029

<151> 1999-05-04

<160> 8

<170> PatentIn Ver. 2.1

<210> 1

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 1

caatgccctc tttatttcc

19

<210> 2

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 2

acttgcttgt atgtcccc

18

<210> 3

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 3

tgaagtggaa tgacaaaggg

20

<210> 4

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 4

aagatggata agagggcgg

19

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 5

acacagtcca agtcagtttc

20

<210> 6

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 6

atccttccca ccttcttc

18

<210> 7

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 7

ggaagtgatt cgaaatgatg tg

22

<210> 8

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 8

tcagaaccac tcccctcata g

21

IN THE UNITED STATES RECEIVING OFFICE (RO/US)

Applicant : The Trustees of Columbia University in the
City of New York

International
Application No.: Not Yet Known

International
Filing Date : Herewith

For : METHOD OF INDUCING FORMATION OF KIDNEY
EPITHELIA FROM MESENCHYMAL PRECURSORS

1185 Avenue of the Americas
New York, New York 10036
May 4, 2000

Honorable Commissioner for Patents
Box PCT
Washington, D.C. 20231


ATTN: RO/US

SIR:

**STATEMENT IN ACCORDANCE WITH 37 C.F.R. §1.821(f)
FOR ABOVE-IDENTIFIED APPLICATION**

Pursuant to 37 C.F.R. §1.821(f), I hereby certify that the contents of the Sequence Listing (3 pages) attached hereto as **Exhibit A** and the contents of the computer readable form of the sequence listings are identical.

Respectfully submitted,


Jennifer H. Burdman
Registration No. 44,574
c/o Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400